Zimmer Biomet Holdings, Inc. (ZBH) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 18/100
- 10Y CAGR
- 3.2%
- Median YoY
- 3%
- YoY volatility
- σ 10.7pp· uneven
- Quarters ≥ 20%
- 1 of 40
- Negative quarters
- 12
- Valuation vs own 10Y history
- P/S 2.3x · 10Y median 3.1x · 7th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 1 of 40 → 1 of 40 pts
- Steadiness (typical swing 10.7pp) → 17.4 of 25 pts
- Pace (median 3% YoY) → 0 of 20 pts
- Latest quarter (4.8% YoY) → 0 of 15 pts
- Score: 18 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 3.2% | 3% | 10.7pp | 1 of 40 | 12 |
| EPSEPS | 29.9% | 5.8% | 431.7pp | 12 of 30 | 13 |
| Op cash flowOperating cash flow | 7% | 3.8% | 44.4pp | 9 of 39 | 16 |
| EBITDAEBITDA | 7.6% | 2.6% | 84.4pp | 5 of 36 | 15 |
| FCFFree cash flow | 7.8% | 6.9% | 104.4pp | 15 of 39 | 18 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: ZBH on the compounders surface · All compounders, ranked